SCHEMBL20554

SCHEMBL20554

COC(=O)C1CC2=CC(=O)CCC2(C)C2(C)CCC3C(CCC34CCC(=O)O4)C12

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PGR P06401 8/20 0.58
NR3C1 P04150 7/20 0.58
AR P10275 6/20 0.58
NR3C2 P08235 3/20 0.58
LMNA P02545 5/20 0.40
HTR2B P41595 3/20 0.40
CHRM2 P08172 3/20 0.40
ADRA1A P35348 2/20 0.40
CYP2C19 P33261 2/20 0.40
MAPT P10636 2/20 0.40
BLM P54132 2/20 0.40
ABCB11 O95342 2/20 0.40
CYP3A4 P08684 2/20 0.40
OPRK1 P41145 2/20 0.40
NFKB1 P19838 1/20 0.40
HIF1A Q16665 1/20 0.40
ESR1 P03372 1/20 0.40
ABCB1 P08183 1/20 0.40
ESR2 Q92731 1/20 0.40
SLC47A1 Q96FL8 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL120657 0.92 PGR (0.49) PGRNR3C1ARNR3C2LMNA
SCHEMBL14598809 0.84 PGR (0.66) PGRNR3C1ARNR3C2LMNA
SCHEMBL5395577 0.78 SHBG (0.46) PGRNR3C1ARLMNAHTR2B
SCHEMBL14284887 0.75 NR3C1 (0.71) PGRNR3C1ARNR3C2LMNA
SCHEMBL14450063 0.75 NR3C1 (0.71) PGRNR3C1ARNR3C2LMNA
SCHEMBL18387204 0.74 NR3C1 (0.74) PGRNR3C1ARNR3C2LMNA
SCHEMBL14592050 0.74 NR3C1 (0.74) PGRNR3C1ARNR3C2LMNA
SCHEMBL14284956 0.74 NR3C1 (0.74) PGRNR3C1ARNR3C2LMNA
SCHEMBL19505433 0.74 NR3C1 (0.74) PGRNR3C1ARNR3C2LMNA
Eplerenone SCHEMBL14308852 0.73 NR3C1 (1.00) PGRNR3C1ARNR3C2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 420 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260027139-A1 TREATMENT OF SLEEP APNEA WITH A COMBINATION OF A CARBONIC ANHYDRASE INHIBITOR AND AN ALDOSTERONE ANTAGONIST VIVUS, INC. 2026-01-29 US claimed
US-20250295634-A1 USE OF ANTIANDROGENS TO TREAT SEPSIS RHODE ISLAND HOSPITAL 2025-09-25 US claimed
US-20240424053-A1 METHODS AND COMPOSITIONS FOR PROVIDING MYOCARDIAL PROTECTION AND TREATING MYOCARDIAL STRESS AND FIBROSIS TUFTS MEDICAL CENTER, INC. 2024-12-26 US claimed
EP-3265103-B1 COMPOSITIONS COMPRISING AN ALDOSTERONE ANTAGONIST FOR USE IN TREATING DRY EYES YEE RICHARD W (US) 2024-07-24 EP claimed
US-20240173337-A1 METHODS AND COMPOSITIONS FOR TREATING SLEEP APNEA APNIMED, INC. (DELAWARE) 2024-05-30 US claimed
US-20240139224-A1 TREATMENT OF SLEEP APNEA WITH A COMBINATION OF A CARBONIC ANHYDRASE INHIBITOR AND AN ALDOSTERONE ANTAGONIST AMERICAN ENTERTAINMENT PROPERTIES CORP., AS LENDER 2024-05-02 US claimed
EP-4313153-A1 METHODS AND COMPOSITIONS FOR TREATING SLEEP APNEA APNIMED, INC. (DELAWARE) (US) 2024-02-07 EP claimed
WO-2023086390-A1 METHODS AND COMPOSITIONS FOR PROVIDING MYOCARDIAL PROTECTION AND TREATING MYOCARDIAL STRESS AND FIBROSIS TUFTS MEDICAL CENTER, INC. (US) 2023-05-19 WO claimed
WO-2022204228-A1 METHODS AND COMPOSITIONS FOR TREATING SLEEP APNEA APNIMED, INC. (DELAWARE) (US) 2022-09-29 WO claimed
US-20220175758-A1 COMPOSITIONS AND METHODS TO TREAT NON-ALCOHOLIC FATTY LIVER DISEASES (NAFLD) Coherus Biosciences, Inc. 2022-06-09 US claimed
US-20020019522-A1 Processes for preparation of 9-11, epoxy steroids and intermediates useful therein NG JOHN S (US) 2002-02-14 US claimed
US-20020016455-A1 Processes for preparation of 9,11- epoxy steroids and intermediates useful therein NG JOHN S (US) 2002-02-07 US claimed
EP-1167381-A2 Process for preparation of 7 alpha-carboxyl 9,11-epoxy steroids and Intermediates useful therein G.D. Searle & Co. (US) 2002-01-02 EP claimed
CN-1253564-A Process for the preparation of 9, 11-epoxy steroids and intermediates useful therein SEARLE & CO (US) 2000-05-17 CN claimed
EP-0973791-A2 PROCESS FOR PREPARATION OF 7 ALPHA-CARBOXYL 9, 11-EPOXY STEROIDS AND INTERMEDIATES USEFUL THEREIN AND A GENERAL PROCESS FOR THE EPOXIDATION OF OLIFINIC DOUBLE BONDS G.D. Searle & Co. (US) 2000-01-26 EP claimed
EP-0944644-A2 PROCESSES FOR PREPARATION OF 9,11-EPOXY STEROIDS AND INTERMEDIATES USEFUL THEREIN G.D. Searle & Co. (US) 1999-09-29 EP claimed
CN-1209136-A Process for the preparation of 7 alpha-carboxy 9, 11-epoxy steroids and intermediates used therein and general process for the epoxidation of olefinic double bonds G D SEARRLE AND CO (US) 1999-02-24 CN claimed
WO-1998025948-A9 PROCESSES FOR PREPARATION OF 9,11-EPOXY STEROIDS AND INTERMEDIATES USEFUL THEREIN 1998-11-19 WO claimed
WO-1998025948-A2 PROCESSES FOR PREPARATION OF 9,11-EPOXY STEROIDS AND INTERMEDIATES USEFUL THEREIN G.D. SEARLE & CO. (US) 1998-06-18 WO claimed
WO-1997021720-A2 PROCESSES FOR PREPARATION OF 7 ALPHA-CARBOXYL 9,11-EPOXY STEROIDS AND INTERMEDIATES USEFUL THEREIN AND A GENERAL PROCESS FOR THE EPOXIDATION OF OLIFINIC DOUBLE BONDS G.D. SEARLE AND CO. (US) 1997-06-19 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260027139-A1 TREATMENT OF SLEEP APNEA WITH A COMBINATION OF A CARBONIC ANHYDRASE INHIBITOR AND AN ALDOSTERONE ANTAGONIST CYP21A2, HSD11B2, CA2 PGR 3309/4885NR3C1 187/4885AR 383/4885
US-20220175758-A1 COMPOSITIONS AND METHODS TO TREAT NON-ALCOHOLIC FATTY LIVER DISEASES (NAFLD) SLC10A1, LIPC, FABP1 PGR 4156/4885NR3C1 491/4885AR 3137/4885
US-20250295634-A1 USE OF ANTIANDROGENS TO TREAT SEPSIS SHBG, AR, HSD17B11 PGR 1315/4885NR3C1 53/4885AR 2/4885
US-20240139224-A1 TREATMENT OF SLEEP APNEA WITH A COMBINATION OF A CARBONIC ANHYDRASE INHIBITOR AND AN ALDOSTERONE ANTAGONIST CA4, CA9, CA7 PGR 4018/4885NR3C1 143/4885AR 643/4885
US-20020019522-A1 Processes for preparation of 9-11, epoxy steroids and intermediates useful therein CYP4A11, HSD11B1, DHCR7 PGR 1062/4885NR3C1 32/4885AR 205/4885
US-20020016455-A1 Processes for preparation of 9,11- epoxy steroids and intermediates useful therein CYP4A11, HSD11B1, DHCR7 PGR 1034/4885NR3C1 36/4885AR 210/4885
US-20240424053-A1 METHODS AND COMPOSITIONS FOR PROVIDING MYOCARDIAL PROTECTION AND TREATING MYOCARDIAL STRESS AND FIBROSIS TNNT2, TNNI3, MMP1 PGR 2077/4885NR3C1 796/4885AR 3143/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.